Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 5/20 | 0.67 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.64 |
| ▸ | PYGL | P06737 | 1/20 | 0.57 |
| ▸ | PYGM | P11217 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | STK39 | Q9UEW8 | 2/20 | 0.54 |
| ▸ | PRSS12 | P56730 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2270287 | 0.90 | PYGM (0.70) | ACLYSERPINE1PYGLPYGMMEN1 | |
| SCHEMBL2272043 | 0.90 | SERPINE1 (0.75) | SERPINE1MEN1PKMKMT2ANPSR1 | |
| SCHEMBL2273110 | 0.90 | SERPINE1 (0.60) | ACLYSERPINE1PYGLPYGMMEN1 | |
| SCHEMBL2272347 | 0.88 | SERPINE1 (0.69) | ACLYSERPINE1PYGLPYGMMEN1 | |
| SCHEMBL2271588 | 0.88 | SERPINE1 (0.64) | SERPINE1PYGLPYGMMEN1PKM | |
| SCHEMBL2274838 | 0.86 | SERPINE1 (0.66) | ACLYSERPINE1PYGLPYGMMEN1 | |
| SCHEMBL2273564 | 0.85 | HDAC1 (0.61) | SERPINE1MEN1PKMKMT2ANPSR1 | |
| SCHEMBL2276447 | 0.85 | SERPINE1 (0.54) | SERPINE1PYGLPYGMPRSS12 | |
| SCHEMBL2274217 | 0.85 | CYP2C9 (0.57) | SERPINE1PYGLPYGMMEN1KMT2A | |
| SCHEMBL2270119 | 0.84 | PPARG (0.64) | ACLYSERPINE1PYGLPYGMMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999132-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| CN-101094829-A | Novel anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO LTD (JP) | 2007-12-26 | — | — | CN | disclosed |
| EP-1820795-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP26, MMP11 | ACLY 653/4885SERPINE1 101/4885PYGL 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.